Cargando…
AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin
AS1411 binds nucleolin (NCL) and is the first oligodeoxynucleotide aptamer to reach phase I and II clinical trials for the treatment of several cancers. However, the mechanisms by which AS1411 targets and kills glioma cells and tissues remain unclear. Here we report that AS1411 induces cell apoptosi...
Autores principales: | Cheng, Ye, Zhao, Gang, Zhang, Siwen, Nigim, Fares, Zhou, Guangtong, Yu, Zhiyun, Song, Yang, Chen, Yong, Li, Yunqian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132312/ https://www.ncbi.nlm.nih.gov/pubmed/27907160 http://dx.doi.org/10.1371/journal.pone.0167094 |
Ejemplares similares
-
Insights into the binding mode of AS1411 aptamer to nucleolin
por: Bie, Lihua, et al.
Publicado: (2022) -
Anti-nucleolin aptamer AS1411: an advancing therapeutic
por: Van den Avont, Alexander, et al.
Publicado: (2023) -
AS1411 Nucleolin-Specific Binding Aptamers Reduce Pathological Angiogenesis through Inhibition of Nucleolin Phosphorylation
por: Iturriaga-Goyon, Emilio, et al.
Publicado: (2021) -
Locking up the AS1411 Aptamer with a Flanking Duplex: Towards an Improved Nucleolin-Targeting
por: Miranda, André, et al.
Publicado: (2021) -
Evaluation of somatostatin and nucleolin receptors for therapeutic delivery in non-small cell lung cancer stem cells applying the somatostatin-analog DOTATATE and the nucleolin-targeting aptamer AS1411
por: Holmboe, Sif, et al.
Publicado: (2017)